Junfeng Liang - Publications

Stevens Institute of Technology 
Microbiology Biology, Cell Biology

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Chen L, Liang JF. The potential roles of cell surface pHs in bioactive peptide activation. Chemical Biology & Drug Design. 85: 208-15. PMID 24925341 DOI: 10.1111/cbdd.12374  0.68
2012 Kharidia R, Tu Z, Chen L, Liang JF. Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria. Archives of Microbiology. 194: 769-78. PMID 22526264 DOI: 10.1007/s00203-012-0810-5  1
2012 Chen L, Tu Z, Voloshchuk N, Liang JF. Lytic peptides with improved stability and selectivity designed for cancer treatment. Journal of Pharmaceutical Sciences. 101: 1508-17. PMID 22227945 DOI: 10.1002/Jps.23043  0.44
2011 Kharidia R, Liang JF. The activity of a small lytic peptide PTP-7 on Staphylococcus aureus biofilms. Journal of Microbiology (Seoul, Korea). 49: 663-8. PMID 21887652 DOI: 10.1007/s12275-011-1013-5  1
2009 Tu Z, Young A, Murphy C, Liang JF. The pH sensitivity of histidine-containing lytic peptides. Journal of Peptide Science : An Official Publication of the European Peptide Society. 15: 790-5. PMID 19787821 DOI: 10.1002/psc.1180  0.68
2009 Tu Z, Volk M, Shah K, Clerkin K, Liang JF. Constructing bioactive peptides with pH-dependent activities. Peptides. 30: 1523-8. PMID 19464332 DOI: 10.1016/j.peptides.2009.05.009  0.68
2009 Li YT, Kwon YM, Spangrude GJ, Liang JF, Chung HS, Park YJ, Yang VC. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. Journal of Biomedical Materials Research. Part A. 91: 209-20. PMID 18814276 DOI: 10.1002/Jbm.A.32204  0.44
2008 Kharidia R, Friedman KA, Liang JF. Improved gene expression using low molecular weight peptides produced from protamine sulfate. Biochemistry. Biokhimii͡A. 73: 1162-8. PMID 18991564 DOI: 10.1134/S0006297908100143  0.44
2008 Kwon YM, Li YT, Liang JF, Park YJ, Chang LC, Yang VC. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 130: 252-8. PMID 18652856 DOI: 10.1016/J.Jconrel.2008.06.017  0.44
2008 Agresti C, Tu Z, Ng C, Yang Y, Liang JF. Specific interactions between diphenhydramine and alpha-helical poly(glutamic acid)--a new ion-pairing complex for taste masking and pH-controlled diphenhydramine release. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 70: 226-33. PMID 18514496 DOI: 10.1016/j.ejpb.2008.04.004  0.68
2007 Tu Z, Hao J, Kharidia R, Meng XG, Liang JF. Improved stability and selectivity of lytic peptides through self-assembly. Biochemical and Biophysical Research Communications. 361: 712-7. PMID 17678628 DOI: 10.1016/j.bbrc.2007.06.178  1
2005 Yang VC, Naik SS, Song H, Dombkowski AA, Crippen G, Liang JF. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. Journal of Controlled Release : Official Journal of the Controlled Release Society. 110: 164-76. PMID 16260060 DOI: 10.1016/J.Jconrel.2005.09.027  0.44
2005 Wang T, Yang Z, Emregul E, David A, Balthasar JP, Liang J, Yang VC. Strategies for improving the functionality of an affinity bioreactor. International Journal of Pharmaceutics. 306: 132-41. PMID 16246511 DOI: 10.1016/J.Ijpharm.2005.09.011  0.44
2005 Liang JF, Yang VC. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorganic & Medicinal Chemistry Letters. 15: 5071-5. PMID 16168650 DOI: 10.1016/J.Bmcl.2005.07.087  0.44
2005 Liang JF, Yang VC, Vaynshteyn Y. The minimal functional sequence of protamine. Biochemical and Biophysical Research Communications. 336: 653-9. PMID 16139792 DOI: 10.1016/j.bbrc.2005.08.151  0.44
2005 Liang JF, Yang VC. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochemical and Biophysical Research Communications. 335: 734-8. PMID 16115469 DOI: 10.1016/j.bbrc.2005.07.142  0.44
2005 Park YJ, Chang LC, Liang JF, Moon C, Chung CP, Yang VC. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1555-7. PMID 16033808 DOI: 10.1096/Fj.04-2322Fje  0.44
2003 Park YJ, Liang JF, Ko KS, Kim SW, Yang VC. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. The Journal of Gene Medicine. 5: 700-11. PMID 12898639 DOI: 10.1002/Jgm.402  0.44
2001 Chang LC, Liang JF, Lee HF, Lee LM, Yang VC. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. Aaps Pharmsci. 3: E18. PMID 11741269 DOI: 10.1208/Ps030318  0.44
2001 Tsui B, Singh VK, Liang JF, Yang VC. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue Thrombosis Research. 101: 417-420. PMID 11297758 DOI: 10.1016/S0049-3848(00)00427-8  0.44
2000 Liang JF, Li YT, Connell ME, Yang VC. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system. Aaps Pharmsci. 2: E7. PMID 11741223 DOI: 10.1208/ps020107  0.44
2000 Song H, Liang JF, Yang VC. A prodrug approach for delivery of t-PA: Construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct Asaio Journal. 46: 663-668. PMID 11110262 DOI: 10.1097/00002480-200011000-00005  0.44
Show low-probability matches.